Maaike de Boer - Concepedia

Author

Maaike de Boer

Also Known As

Boer, Maaike De, M De Boer, M de Boer, M. De Boer, M. de Boer, Maaike De Boer, Maaike de Boer, Michel de Boer, Nobumoto Tomioka

114

Publications

4.2K

Citations

H-Index

Concepts

All Affiliations

Radboud University Nijmegen Maastricht University Maastricht University Medical Centre Radboud University Medical Center Zuyderland Medisch Centrum

About

Maaike de Boer is an author at Radboud University Nijmegen specializing in medicine, oncology, and breast cancer.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	16	21	1.5K
2	Health Sciences	9	9	245
3	Engineering	2	2	119
4	Nursing	2	2	90
5	Biostatistics	2	2	53

Maaike de Boer

Publications

3.7K

Citations

H-Index

Page 1

	Year	Citations
Micrometastases or Isolated Tumor Cells and the Outcome of Breast Cancer Maaike de Boer, Carolien H. M. van Deurzen, J.A.A.M. van Dijck, New England Journal of Medicine	2009	528
Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer Charles E. Geyer, Judy E. Garber, Richard D. Gelber, Annals of Oncology Breast OncologyOverall SurvivalMedicinePathologyGermline Pathogenic Variants	2022	404
Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer Hope S. Rugo, Seock‐Ah Im, Fátima Cardoso, JAMA Oncology	2021	336
Prognosis of metastatic breast cancer subtypes: the hormone receptor/HER2-positive subtype is associated with the most favorable outcome D.J.A. Lobbezoo, Roel J.W. van Kampen, Adri C. Voogd, Breast Cancer Research and Treatment Breast OncologyMedicinePathologyCancer PrognosisFavorable Outcome	2013	239
Prognosis of metastatic breast cancer: are there differences between patients with de novo and recurrent metastatic breast cancer? D.J.A. Lobbezoo, Roel J.W. van Kampen, Adri C. Voogd, British Journal of Cancer	2015	233
Extended adjuvant aromatase inhibition after sequential endocrine therapy (DATA): a randomised, phase 3 trial Vivianne C. G. Tjan‐Heijnen, Irene E.G. van Hellemond, Petronella G.M. Peer, The Lancet Oncology MedicineClinical TrialsGynecologyBreast CancerAromatase	2017	157
Clinical tumor stage is the most important predictor of pathological complete response rate after neoadjuvant chemotherapy in breast cancer patients B. Goorts, Thiemo J. A. van Nijnatten, Linda de Munck, Breast Cancer Research and Treatment	2017	129
Docetaxel (Taxotere): an active agent in metastatic urothelial cancer; results of a phase II study in non-chemotherapy-pretreated patients Ronald de Wit, WHJ Kruit, G. Stoter, British Journal of Cancer Metastatic Urothelial CancerUrologyGenitourinary CancerMedicinePharmacology	1998	112
Regional Recurrence in Breast Cancer Patients With Sentinel Node Micrometastases and Isolated Tumor Cells Manon J. Pepels, Maaike de Boer, Peter Bult, Annals of Surgery	2011	107
A Novel Less-invasive Approach for Axillary Staging After Neoadjuvant Chemotherapy in Patients With Axillary Node-positive Breast Cancer by Combining Radioactive Iodine Seed Localization in the Axilla With the Sentinel Node Procedure (RISAS): A Dutch Prospective Multicenter Validation Study Thiemo J. A. van Nijnatten, Janine M. Simons, Marjolein L. Smidt, Clinical Breast Cancer Sentinel Node ProcedureSurgical OncologyBreast OncologyNeoadjuvant ChemotherapyMedicine	2017	104

Page 1